Public Health Initiatives

To Meaningfully Address the Opioid Crisis, Purdue is Pursuing Three Public Health Initiatives

The Initiatives seek to increase access to treatments for opioid use disorder and opioid overdose by developing and providing, at no profit, millions of doses of the following medicines:

1. Opioid Use Disorder Treatment – Buprenorphine/Naloxone Sublingual Tablets (generic equivalent to Suboxone®)

Purdue has partnered with MMCAP Infuse, a national cooperative group purchasing organization, to provide this medication to correctional facilities for incarcerated individuals with opioid use disorder. Under the agreement, to increase access to treatment for incarcerated individuals, Purdue will provide approximately 1.25 million tablets for distribution at the cost of one penny ($0.01) per tablet. Read more here.

Click here for Prescribing Information.

2.  Opioid Overdose Treatment – Injectable Nalmefene

Nalmefene HCl injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and is indicated in the management of known or suspected opioid overdose. Additional delivery formats* of Nalmefene HCl are in development. Nalmefene HCl injection is FDA-approved and available to purchase through Authorized Distributors at no profit to Purdue.

Click here to learn more, and here for Prescribing Information.

*These products are not approved by the U.S. Food and Drug Administration, and safety or effectiveness have not been established. There is no guarantee that these products will successfully complete development or gain FDA approval.

The above efforts supplement the work Purdue has done to assist Harm Reduction Therapeutics (HRT) with the development and FDA approval of RiVive™:

3.  Opioid Overdose Treatment – Over-the-Counter (OTC) Naloxone Nasal Spray

HRT is an independent, non-profit pharmaceutical company that developed and is distributing the over-the-counter naloxone nasal spray, RiVive™ (Naloxone HCl Nasal Spray 3 mg) for the emergency treatment of opioid overdose. HRT’s mission is to save lives that would have otherwise been lost to opioid overdose by making OTC low-price naloxone available to everyone in the United States. Since 2018, Purdue has supported HRT’s mission by contributing tens of millions of dollars, extensive technical expertise, and rights to important data to support the development of this important medication. HRT is distributing RiVive at cost or below cost and no company, individual, or entity will profit from the sale of RiVive. Click here to learn more.

Privacy Policy Updates

Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.